American Heart Journal
Volume 156, Issue 1 , Pages 13-22, July 2008

Body mass index and mortality in heart failure: A meta-analysis

  • Antigone Oreopoulos, MSc

      Affiliations

    • Department of Clinical Epidemiology, School of Public Health, University of Alberta, Edmonton, Alberta, Canada
  • ,
  • Raj Padwal, MD, MSc

      Affiliations

    • Division of General Internal Medicine, University of Alberta, Edmonton, Alberta, Canada
    • Corresponding Author InformationReprint requests: Raj Padwal, MD, MSc, Division of General Internal Medicine, University of Alberta, 2E3.22 Walter C. Mackenzie Health Sciences Center, 8440-112 Street, Edmonton, Alberta, Canada T6G 2B7.
  • ,
  • Kamyar Kalantar-Zadeh, MD, MPH, PhD

      Affiliations

    • Division of Nephrology and Hypertension, Harbor-UCLA Medical Center, Torrance, CA
  • ,
  • Gregg C. Fonarow, MD, FACC

      Affiliations

    • Division of Cardiology, UCLA David Geffen School of Medicine, Los Angeles, CA
  • ,
  • Colleen M. Norris, PhD

      Affiliations

    • Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada
  • ,
  • Finlay A. McAlister, MD, MSc

      Affiliations

    • Division of General Internal Medicine, University of Alberta, Edmonton, Alberta, Canada

Received 5 November 2007; accepted 14 February 2008.

Background

In patients with chronic heart failure (CHF), previous studies have reported reduced mortality rates in patients with increased body mass index (BMI). The potentially protective effect of increased BMI in CHF has been termed the obesity paradox or reverse epidemiology. This meta-analysis was conducted to examine the relationship between increased BMI and mortality in patients with CHF.

Methods

We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Scopus, and Web of Science to identify studies with contemporaneous control groups (cohort, case-control, or randomized controlled trials) that examined the effect of obesity on all-cause and cardiovascular mortality. Two reviewers independently assessed studies for inclusion and performed data extraction.

Results

Nine observational studies met final inclusion criteria (total n = 28,209). Mean length of follow-up was 2.7 years. Compared to individuals without elevated BMI levels, both overweight (BMI ∼25.0-29.9 kg/m2, RR 0.84, 95% CI 0.79-0.90) and obesity (BMI ∼≥30 kg/m2, RR 0.67, 95% CI 0.62-0.73) were associated with lower all-cause mortality. Overweight (RR 0.81, 95% CI 0.72-0.92) and obesity (RR 0.60, 95% CI 0.53-0.69) were also associated with lower cardiovascular mortality. In a risk-adjusted sensitivity analysis, both obesity (adjusted HR 0.88, 95% CI 0.83-0.93) and overweight (adjusted HR 0.93, 95% CI 0.89-0.97) remained protective against mortality.

Conclusions

Overweight and obesity were associated with lower all-cause and cardiovascular mortality rates in patients with CHF and were not associated with increased mortality in any study. There is a need for prospective studies to elucidate mechanisms for this relationship.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 There was no project specific funding, but A.O. is supported by a CIHR Strategic Training Fellowship in Tomorrow's Research Cardiovascular Health Professionals; C.M.N. is supported by career salary awards from the Alberta Heritage Foundation for Medical Research; C.M.N. is also supported by New Investigator Awards from the Canadian Institutes of Health Research; G.C.F. is supported by a grant from the National Heart Lung and Blood Institute and the Eliot Corday Foundation; K.K. is supported by a grant from the National Institute of Diabetes, Digestive and Kidney Disease from the NIH and by a Grant-in-Aid from the American Heart Association; and F.A.M. is supported by career salary awards from AHFMR and CIHR as well as the Patient Health Management Chair at the University of Alberta.

PII: S0002-8703(08)00154-3

doi:10.1016/j.ahj.2008.02.014

American Heart Journal
Volume 156, Issue 1 , Pages 13-22, July 2008